Skip to main content
Journal cover image

Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE.

Publication ,  Journal Article
Jerjes-Sánchez, C; Rodriguez, D; Farjat, AE; Kayani, G; MacCallum, P; Lopes, RD; Turpie, AGG; Weitz, JI; Haas, S; Ageno, W; Goto, S ...
Published in: TH Open
January 2021

Introduction  The risk of venous thromboembolism (VTE) increases during pregnancy and the puerperium such that VTE is a leading cause of maternal mortality. Methods  We describe the clinical characteristics, diagnostic strategies, treatment patterns, and outcomes of women with pregnancy-associated VTE (PA-VTE) enrolled in the Global Anticoagulant Registry in the FIELD (GARFIELD)-VTE. Women of childbearing age (<45 years) were stratified into those with PA-VTE ( n  = 183), which included pregnant patients and those within the puerperium, and those with nonpregnancy associated VTE (NPA-VTE; n  = 1,187). Patients with PA-VTE were not stratified based upon the stage of pregnancy or puerperium. Results  Women with PA-VTE were younger (30.5 vs. 34.8 years), less likely to have pulmonary embolism (PE) (19.7 vs. 32.3%) and more likely to have left-sided deep vein thrombosis (DVT) (73.9 vs. 54.8%) compared with those with NPA-VTE. The most common risk factors in PA-VTE patients were hospitalization (10.4%), previous surgery (10.4%), and family history of VTE (9.3%). DVT was typically diagnosed by compression ultrasonography (98.7%) and PE by chest computed tomography (75.0%). PA-VTE patients more often received parenteral (43.2 vs. 15.1%) or vitamin K antagonists (VKA) (9.3 vs. 7.6%) therapy alone. NPA-VTE patients more often received a DOAC alone (30.2 vs. 13.7%). The risk (hazard ratio [95% confidence interval]) of all-cause mortality (0.59 [0.18-1.98]), recurrent VTE (0.82 [0.34-1.94]), and major bleeding (1.13 [0.33-3.90]) were comparable between PA-VTE and NPA-VTE patients. Uterine bleeding was the most common complication in both groups. Conclusion  VKAs or DOACs are widely used for treatment of PA-VTE despite limited evidence for their use in this population. Rates of clinical outcomes were comparable between groups.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

TH Open

DOI

EISSN

2512-9465

Publication Date

January 2021

Volume

5

Issue

1

Start / End Page

e24 / e34

Location

Germany
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Jerjes-Sánchez, C., Rodriguez, D., Farjat, A. E., Kayani, G., MacCallum, P., Lopes, R. D., … GARFIELD-VTE investigators, . (2021). Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. TH Open, 5(1), e24–e34. https://doi.org/10.1055/s-0040-1722611
Jerjes-Sánchez, Carlos, David Rodriguez, Alfredo E. Farjat, Gloria Kayani, Peter MacCallum, Renato D. Lopes, Alexander G. G. Turpie, et al. “Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE.TH Open 5, no. 1 (January 2021): e24–34. https://doi.org/10.1055/s-0040-1722611.
Jerjes-Sánchez C, Rodriguez D, Farjat AE, Kayani G, MacCallum P, Lopes RD, et al. Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. TH Open. 2021 Jan;5(1):e24–34.
Jerjes-Sánchez, Carlos, et al. “Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE.TH Open, vol. 5, no. 1, Jan. 2021, pp. e24–34. Pubmed, doi:10.1055/s-0040-1722611.
Jerjes-Sánchez C, Rodriguez D, Farjat AE, Kayani G, MacCallum P, Lopes RD, Turpie AGG, Weitz JI, Haas S, Ageno W, Goto S, Goldhaber SZ, Angchaisuksiri P, Nielsen JD, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK, GARFIELD-VTE investigators. Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. TH Open. 2021 Jan;5(1):e24–e34.
Journal cover image

Published In

TH Open

DOI

EISSN

2512-9465

Publication Date

January 2021

Volume

5

Issue

1

Start / End Page

e24 / e34

Location

Germany